Next Article in Journal
Amphetamine-Decreased Progesterone and Estradiol Release in Rat Granulosa Cells: The Regulatory Role of cAMP- and Ca2+-Mediated Signaling Pathways
Next Article in Special Issue
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
Previous Article in Journal
Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study
Previous Article in Special Issue
Natural Products That Changed Society
Review

20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases

1
Biophytis, Sorbonne Université, BC9, 4 place Jussieu, 75005 Paris, France
2
BIOSIPE, IBPS, Sorbonne Université, UPMC, 75005 Paris, France
*
Author to whom correspondence should be addressed.
Academic Editor: Pavel B. Drašar
Biomedicines 2021, 9(5), 492; https://doi.org/10.3390/biomedicines9050492
Received: 2 April 2021 / Revised: 24 April 2021 / Accepted: 26 April 2021 / Published: 29 April 2021
There is growing interest in the pharmaceutical and medical applications of 20-hydroxyecdysone (20E), a polyhydroxylated steroid which naturally occurs in low but very significant amounts in invertebrates, where it has hormonal roles, and in certain plant species, where it is believed to contribute to the deterrence of invertebrate predators. Studies in vivo and in vitro have revealed beneficial effects in mammals: anabolic, hypolipidemic, anti-diabetic, anti-inflammatory, hepatoprotective, etc. The possible mode of action in mammals has been determined recently, with the main mechanism involving the activation of the Mas1 receptor, a key component of the renin–angiotensin system, which would explain many of the pleiotropic effects observed in the different animal models. Processes have been developed to produce large amounts of pharmaceutical grade 20E, and regulatory preclinical studies have assessed its lack of toxicity. The effects of 20E have been evaluated in early stage clinical trials in healthy volunteers and in patients for the treatment of neuromuscular, cardio-metabolic or respiratory diseases. The prospects and limitations of developing 20E as a drug are discussed, including the requirement for a better evaluation of its safety and pharmacological profile and for developing a production process compliant with pharmaceutical standards. View Full-Text
Keywords: anabolic; diabetes; Duchenne muscular dystrophy; β-ecdysone; ecdysteroid; ecdysterone; Mas1; osteoporosis; sarcopenia; COVID-19; cardiometabolic diseases; respiratory diseases anabolic; diabetes; Duchenne muscular dystrophy; β-ecdysone; ecdysteroid; ecdysterone; Mas1; osteoporosis; sarcopenia; COVID-19; cardiometabolic diseases; respiratory diseases
Show Figures

Figure 1

MDPI and ACS Style

Dinan, L.; Dioh, W.; Veillet, S.; Lafont, R. 20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases. Biomedicines 2021, 9, 492. https://doi.org/10.3390/biomedicines9050492

AMA Style

Dinan L, Dioh W, Veillet S, Lafont R. 20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases. Biomedicines. 2021; 9(5):492. https://doi.org/10.3390/biomedicines9050492

Chicago/Turabian Style

Dinan, Laurence, Waly Dioh, Stanislas Veillet, and Rene Lafont. 2021. "20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases" Biomedicines 9, no. 5: 492. https://doi.org/10.3390/biomedicines9050492

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop